

7-21-2011

Alterations In the Transcriptome and Antibiotic Susceptibility of *Staphylococcus aureus* Grown In the Presence of Diclofenac

James T. Riordan
University of South Florida, jtriordan@usf.edu

JoAnne M. Dupre
New Mexico State University

Stephanie A. Cantore-Matyti
New Mexico State University

Atul Kumar-Singh
Illinois State University

Yang Song
Illinois State University

See next page for additional authors

Follow this and additional works at: https://aquila.usm.edu/fac_pubs


 Part of the [Biology Commons](#)

Recommended Citation

Riordan, J. T., Dupre, J. M., Cantore-Matyti, S. A., Kumar-Singh, A., Song, Y., Zaman, S., Horan, S., Helal, N. S., Nagarajan, V., Elasri, M. O., Wilkinson, B. J., Gustafson, J. E. (2011). Alterations In the Transcriptome and Antibiotic Susceptibility of *Staphylococcus aureus* Grown In the Presence of Diclofenac. *Annals of Clinical Microbiology and Antimicrobials*, 10(30), 1-11.
Available at: https://aquila.usm.edu/fac_pubs/15140

Authors

James T. Riordan, JoAnne M. Dupre, Stephanie A. Cantore-Maty, Atul Kumar-Singh, Yang Song, Shahrear Zaman, Sonia Horan, Nada S. Helal, Vijayaraj Nagarajan, Mohamed O. Elasri, Brian J. Wilkinson, and John E. Gustafson



RESEARCH

Open Access

Alterations in the transcriptome and antibiotic susceptibility of *Staphylococcus aureus* grown in the presence of diclofenac

James T Riordan^{1*}, JoAnne M Dupre², Stephanie A Cantore-Matyi², Atul Kumar-Singh³, Yang Song³, Shahrear Zaman², Sonia Horan², Nada S Helal¹, Vijayaraj Nagarajan^{4,5}, Mohamed O Elasi⁴, Brian J Wilkinson³ and John E Gustafson²

Abstract

Background: Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) which has been shown to increase the susceptibility of various bacteria to antimicrobials and demonstrated to have broad antimicrobial activity. This study describes transcriptome alterations in *S. aureus* strain COL grown with diclofenac and characterizes the effects of this NSAID on antibiotic susceptibility in laboratory, clinical and diclofenac reduced-susceptibility (Dc^{RS}) *S. aureus* strains.

Methods: Transcriptional alterations in response to growth with diclofenac were measured using *S. aureus* gene expression microarrays and quantitative real-time PCR. Antimicrobial susceptibility was determined by agar diffusion MICs and gradient plate analysis. Ciprofloxacin accumulation was measured by fluorescence spectrophotometry.

Results: Growth of *S. aureus* strain COL with 80 µg/ml (0.2 × MIC) of diclofenac resulted in the significant alteration by ≥2-fold of 458 genes. These represented genes encoding proteins for transport and binding, protein and DNA synthesis, and the cell envelope. Notable alterations included the strong down-regulation of antimicrobial efflux pumps including *mepRAB* and a putative *emrAB/qacA*-family pump. Diclofenac up-regulated *sigB* (σ^B), encoding an alternative sigma factor which has been shown to be important for antimicrobial resistance. *Staphylococcus aureus* microarray metadatabase (SAMMD) analysis further revealed that 46% of genes differentially-expressed with diclofenac are also σ^B -regulated. Diclofenac altered *S. aureus* susceptibility to multiple antibiotics in a strain-dependent manner. Susceptibility increased for ciprofloxacin, ofloxacin and norfloxacin, decreased for oxacillin and vancomycin, and did not change for tetracycline or chloramphenicol. Mutation to Dc^{RS} did not affect susceptibility to the above antibiotics. Reduced ciprofloxacin MICs with diclofenac in strain BB255, were not associated with increased drug accumulation.

Conclusions: The results of this study suggest that diclofenac influences antibiotic susceptibility in *S. aureus*, in part, by altering the expression of regulatory and structural genes associated with cell wall biosynthesis/turnover and transport.

Keywords: Diclofenac, *S. aureus*, antibiotic resistance, non-steroidal anti-inflammatory drugs (NSAIDs)

Background

Staphylococcus aureus is a human pathogen associated with integumental infections and life-threatening systemic diseases, such as sepsis and endocarditis. The tendency of *S. aureus* to acquire antibiotic resistance has led to the global dissemination of clones expressing multiple

antimicrobial resistance including some that express intermediate or full resistance to the glycopeptide vancomycin [1-3]. Intrinsic mechanisms of antibiotic resistance (i.e. those not acquired by mutation or lateral genetic transfer) in *S. aureus*, might facilitate the acquisition of clinical resistance by allowing for protracted survival in the presence of subinhibitory drug concentrations [4,5]. This could, in part, be achieved by reducing the intracellular concentration of antibiotics due to the up-regulation of drug efflux systems and alterations in membrane

* Correspondence: jtriordan@usf.edu

¹Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL 33620, USA

Full list of author information is available at the end of the article

permeability [6]. Intrinsic resistance mechanisms can be induced upon exposure to antibiotics, as well as chemical repellants, such as the non-steroidal anti-inflammatory drug (NSAID) salicylate [7]. Salicylate, the principal pharmacologically active metabolite of aspirin, has been shown to induce reduced susceptibility to mechanistically-unrelated antimicrobials by both efflux-dependent and -independent mechanisms in *S. aureus* [8-12], and in various Gram-negative bacteria [7]. Salicylates have also been shown to inhibit growth of staphylococci at therapeutically-relevant concentrations [13-15].

The NSAID diclofenac is antibacterial *in vitro*, and administration to mice or rats infected with *Listeria monocytogenes*, *Salmonella typhimurium*, *Mycobacterium tuberculosis* or *S. aureus* has been reported to significantly reduce bacterial pathogen cell counts in blood and in organ homogenates [16-18]. Growth of *E. coli* with inhibitory concentrations ($2 \times \text{MIC}$ or $100 \mu\text{g/ml}$) of diclofenac was shown to reduce the rate of $\text{Ci} (^3\text{H})$ deoxythymidine incorporation into DNA, indicating that diclofenac may target DNA biosynthesis [19]. As for salicylate and other NSAIDs, diclofenac probably acts on multiple targets in the cell. For example, the antibacterial effects of salicylate have been attributed to the down-regulation of adhesins and toxin production [20,21], the alteration of central and energy metabolism [8,22,23], and physicochemical effects on internal pH and membrane potential [24].

Diclofenac has been shown to increase the susceptibility of bacteria *in vitro* to streptomycin and to act synergistically with streptomycin, other aminoglycosides, and cephalosporins to reduce bacterial pathogen counts in animals [25-27]. This could result from any combination of diclofenac-inducible host- or bacteria-specific effects, or through chemical interactions between diclofenac and antibiotics. For example, diclofenac stimulates pro-inflammatory cytokines such as $\text{TNF-}\alpha$ and $\text{IFN-}\gamma$ in BALB/c mice [28], and has been observed to improve the pharmacokinetic properties of ceftriaxone and cefotiam in a rabbit model of experimental *E. coli* endocarditis [26]. Diclofenac may also alter the expression of bacterial antibiotic resistance genes, as has been shown for salicylate [7]. Salicylate is a ligand for transcriptional regulators of multidrug resistance, such as the multiple antibiotic resistance regulator (MarR) protein of *E. coli* [29], and alters the expression of MarR-family genes such as *sarA*, *sarR*, and *mgrA* in *S. aureus* [8,9].

The effect of diclofenac on antimicrobial resistance has thus far been determined for drugs which have limited therapeutic value for *S. aureus* infections. This includes the psychotropic drug trifluoperazine [30], and the aminoglycoside, streptomycin [25]. In addition, the changes in bacterial gene expression which occur in response to diclofenac have not been reported. The present study describes transcriptome alterations in the methicillin-resistant *S. aureus* (MRSA) strain COL when grown with

diclofenac. Furthermore, the effect of diclofenac on the susceptibility of laboratory, and antibiotic-resistant clinical strains to several classes of antibiotics was determined.

Methods

Strains, chemicals and growth conditions

For a complete list of *S. aureus* strains used in this study see Table 1. Strains were stocked in glycerol (20% vol/vol) at -80°C . Working cultures were grown on Mueller Hinton agar (MHA) or tryptic soy agar (TSA) and maintained at 4°C . Overnight cultures (18 h, 37°C , 200 RPM) were prepared by inoculating single colonies into MHB, TSB or Luria Bertani broth (LB). All NSAIDs and antibiotics were purchased from Sigma Chemical Co. (St. Louis, MO), except when indicated. Stocks of ciprofloxacin (kind gift of Bayer Corporation, West Haven CT), ofloxacin, oxacillin, and vancomycin were prepared in double-distilled water, and stocks of chloramphenicol, norfloxacin, and tetracycline were prepared in 100% ethanol. Antibiotic stock solutions (25 mg/ml) were filter-sterilized ($0.2 \mu\text{m}$) and stored at -20°C . NSAID stock solutions of acetaminophen (0.5 M), acetylsalicylic acid (0.5 M) and ibuprofen (0.4 M) were made-up in 100% ethanol; sodium diclofenac (0.15 M) was made up in methanol, and sodium benzoate (1 M) and sodium salicylate (0.5 M) stocks were prepared in distilled water. The effect of diclofenac on growth in TSB was measured for SH1000, COL and diclofenac reduced-susceptibility (Dc^{RS}) mutants by measuring optical density at 580 nm (OD_{580}) every hour for 8 h. For transcriptional analysis, fresh TSB cultures of strain COL were prepared by inoculating at 1:100 (vol/vol) from overnight TSB cultures. Cultures (biological replicates: $N = 4$ arrays; $N = 3$ qRT-PCR) were then grown to exponential phase ($\text{OD}_{580} = 0.5$) before the addition of diclofenac ($80 \mu\text{g/ml}$ final concentration), or an equal volume of sterile methanol (0.16% vol/vol) for microarrays or sterile water for qRT-PCR as controls, and incubated for an additional 15 min before sampling. There was no significant difference in the expression patterns of genes between controls (see results for qRT-PCR validation of microarray genes).

Table 1 Strains used in this study

Strain name	Relevant strain characteristics	Reference
SH1000	Derivative of 8325-4, <i>rsbU</i> ⁺	[85]
SC1	Derivative of SH1000, Dc^{RS}	This study
COL	<i>mec</i> ⁺ , <i>Oxa</i> ^R	[86]
SC4	Derivative of COL, Dc^{RS} , <i>Oxa</i> ^R	This study
BB255	Derivative of NCTC 8325, <i>rsbU</i>	[87]
WBG8287	Clinical isolate, <i>mec</i> ⁺ , <i>Oxa</i> ^R	[12]
WBG9312	Clinical isolate, <i>Cip</i> ^R	[12]
SA1199B	<i>Cip</i> ^R	This study

RNA purification and cDNA synthesis

Purification of RNA and the synthesis of cDNA for microarrays and quantitative real-time PCR (qRT-PCR) followed previously described methods [8,31]. Briefly, samples were added to RNA Protect (Qiagen, Valencia, CA) and processed according to the manufacturer's instructions. Cells were harvested by centrifugation ($8,000 \times g$, 20 min, 4°C) and then resuspended in 1 ml Trizol (Invitrogen, Carlsbad, CA) and processed in an FP120 FastPrep cell disruptor (MP Biomedicals, Irvine, CA). Chloroform was subsequently added to the lysates, followed by centrifugation ($16,000 \times g$, 15 min, 4°C) and RNA was precipitated 1:1 (vol/vol) in 100% ethyl alcohol. The RNA was then purified using the RNeasyTM kit (Qiagen) according to the manufacturer's instructions. Contaminating DNA was removed from purified RNA using DNAfree (Ambion, Austin, TX). For microarrays, cDNA was produced using SuperScript II Reverse Transcriptase (Invitrogen) from 2 μg of total RNA combined with random hexamers, 0.25 mM deoxynucleoside triphosphate, and 0.25 mM aminoallyl-dUTP. For qRT-PCR, cDNA was prepared as above with the exclusion of aminoallyl-dUTP.

S. aureus DNA microarray hybridization and analysis

Hybridization of synthesized cDNAs to *S. aureus* DNA microarrays TIGR slides ver. 6 (http://pfgrc.jcvi.org/index.php/microarray/array_description/staphylococcus_aureus/version6.html) followed previously described protocols [8,31]. Hybridized arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Union City, CA) and LOWESS normalized TIFF images were analyzed using Spotfinder ver. 3.2.1 (JCVI). Statistical analysis was performed using a Significance Analysis of Microarrays (SAM) [32] unpaired contrast, available through the TM4 software package (JCVI). A false discovery rate of 0.05 and at least a 2-fold upregulation or downregulation in expression levels was used to assign a critical cutoff for significance. Microarray data was also compared to published *S. aureus* gene expression microarray datasets using the *Staphylococcus aureus* Microarray Metadatabase (SAMMD) as described [33]. Microarray intensity data files have been deposited in NCBI Gene Expression Omnibus (series accession number GSE30724) (<http://www.ncbi.nlm.nih.gov/geo/>).

Quantitative real-time PCR

Quantitative real-time PCR (qRT-PCR) was used to validate microarray data as described [8]. Control (uninduced) and diclofenac-induced cDNAs were used in qRT-PCR with an iCycler iQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA) and SYBR Green Supermix (Bio-Rad). Gene-specific primers are listed in Additional File 1. Critical threshold values were normalized using the 23S rRNA

gene *rrlA* and the average ($N = 3$ biological replicates; $N = 2$ technical replicates) relative change in gene expression was reported using the method of Pfaffl [34].

Agar diffusion MICs, and the gradient plate technique

For agar diffusion minimum-inhibitory concentration (MIC) determination, overnight *S. aureus* MHB cultures were diluted to an $\text{OD}_{625 \text{ nm}} = 0.01$ in fresh MHB. Two microliters of each diluted culture was then plated onto MHA plates containing increasing concentrations of antibiotic with 0 $\mu\text{g}/\text{ml}$ (control), 32 $\mu\text{g}/\text{ml}$ or 64 $\mu\text{g}/\text{ml}$ of diclofenac, or diclofenac alone (control). Plates were allowed to air-dry (approx. 15 min), and were then inverted and incubated at 37°C for 24 h. The MIC was determined as the lowest concentration of antibiotic (with and without diclofenac) at which there was no visible growth. Gradient plates were utilized to determine the effect of diclofenac on antibiotic and NSAID susceptibility as described [35]. Differences in average ($N = 3$) MICs or distance (mm) grown into gradient plates were analyzed statistically by analysis of variance.

Ciprofloxacin accumulation assay

Ciprofloxacin accumulation assays were performed using a Hitachi F2000 Fluorescent Spectrophotometer (Hitachi High Technologies America, Inc., Schaumburg, Ill) as described [10,36], and using exponential ($\text{OD}_{580} = 0.5$) cultures of strain BB255 grown in LB (control) or LB containing 32 $\mu\text{g}/\text{ml}$ diclofenac. Differences in ciprofloxacin accumulation (ng antibiotic/mg dry cell weight) were analyzed using a Student's *t*-test, $N = 6$.

Results

The transcriptome of *S. aureus* grown in the presence of diclofenac

Gene expression microarray analysis was used to measure transcriptome alterations in response to growth in the presence of a subinhibitory concentration of diclofenac. The addition of 80 $\mu\text{g}/\text{ml}$ diclofenac to exponential cultures of *S. aureus* strain COL resulted in the significant alteration in expression by ≥ 2 -fold of 458 genes, representing 16.8% (458/2723) of COL genome ORFs (GenBank:CP000046); 226 of which were up-regulated, and 232 down-regulated (Additional File 2). The prevailing ontology of altered genes included those involved in transport and binding (61/459), protein synthesis (32/459) and the cell envelope (24/459). In addition, genes encoding hypothetical proteins represented 33.1% (152/459) of those significantly altered (Additional File 3).

Genes involved with resistance to antibiotics, disinfectants, and antimicrobial peptides were altered during growth with diclofenac. Many of these were down-regulated. For example, *mepR*, encoding a multiple antibiotic resistance regulator (MarR)-family protein

was down-regulated -2.8-fold. MarR is a transcriptional repressor of the *marRAB* operon in *E. coli*. The expression of *marRAB* is important for *E. coli* multidrug resistance, and has been shown to be induced by salicylate [27,29,37]. Kaatz et al. [38] reported an increase in expression of *mepR* in multidrug-resistant *S. aureus*, in addition to two genes directly downstream and contiguous with *mepR*, which together constitute the *mepRAB* operon. The *mepA* gene encodes a multidrug and toxin family extrusion (MATE) efflux pump, and *mepB* encodes a hypothetical protein of unknown function. MepRAB confers reduced susceptibility to fluoroquinolones, tigecycline, and various biocides [39,40]. Importantly, diclofenac induction also led to the down-regulation of *mepA* (-9.2-fold) and *mepB* (-2.8-fold), revealing that the *mepRAB* operon is being repressed in its presence.

Growth with diclofenac also led to the down-regulation (-24.2-fold) of a TetR-family regulator, SACOL2593. TetR-family proteins are broadly distributed among bacteria, and have been shown to reduce expression of antimicrobial resistance through negative regulation of drug transporters [41]. For example, the *S. aureus* TetR regulator QacR represses transcription of *qacA*, encoding a major facilitator superfamily (MFS) drug transporter important for resistance to antiseptics [42,43]. TetR-family proteins also control genes involved in metabolism and in adaptation to changing environments or stressors [41]. SACOL2593 shares only 14% amino acid identity with QacR, and is similarly limited in homology with other characterized TetR-family regulators, but it is conserved among sequenced *S. aureus* strains in GenBank.

Four genes encoding putative MFS drug transporters were altered in response to diclofenac. Only one of these, SACOL0086, was up-regulated (3-fold) and its function is unknown. SACOL0086 shares 69% amino acid identity with the putative EmrB/QacA drug transporter SACOL1475, and 59% and 36% identity with the MFS transporters SACOL2449 and SACOL026, respectively. Down-regulated MFS transporters included SACOL2347 (-12.8-fold) and SACOL2348 (-40.7-fold), encoding an EmrB/QacA- and an EmrA-family drug efflux system, respectively. The *E. coli* multidrug efflux system (*emrRAB*) confers resistance to various antimicrobials, including quinolone antibiotics [44,45]. EmrR is a MarR-family repressor of *emrAB*, and like *marRAB*, the *emr* operon is inducible by salicylate [45]. Interestingly, Delgado et al. [31] observed a 17-fold up-regulation of SACOL2347 in the presence of fusidic acid, indicating that the expression of this putative efflux system is sensitive to both NSAIDs and antibiotics. Immediately downstream of SACOL2347-2348 is the divergently-transcribed gene SACOL2349, which encodes a conserved but uncharacterized TetR/AraC-family regulator; this gene was not, however, significantly altered in

expression. Also down-regulated was the uncharacterized MFS drug transporter, SACOL2159 (-2-fold), and a multiple resistance and pH adaptation (MRP)-type transporter SACOL2156 (-2.2-fold).

Several cell envelope genes linked to antibiotic resistance were altered in response to diclofenac. This included the down-regulation of penicillin-binding protein genes *pbpB* (-3-fold) and *pbp4* (-2.3-fold), which are involved in peptidoglycan biosynthesis and cell growth. Mutations which inactivate *pbp4* have been identified in vancomycin resistant strains selected in the laboratory [46]. In addition, the *dlt* operon genes *dltAB*, encoding proteins involved in D-alanine metabolism were also down-regulated. Mutations in this operon have been shown to increase the sensitivity of *S. aureus* to antimicrobial peptides [47].

Diclofenac induction was observed to up-regulate *sigB* (2-fold) encoding σ^B , an alternative sigma factor which directs the transcription of more than one hundred genes in response to stressors [48,49]. An intact *sigB* has been determined to be important for intrinsic antimicrobial resistance in *S. aureus* [35], and *sigB* is up-regulated by salicylate [9]. Diclofenac was also found to up-regulate *rsbW* by 2.3-fold. This gene encodes an anti- σ^B protein that sequesters cytosolic σ^B and interferes with its ability to associate with RNA polymerase [50]. σ^B is largely regulated at the post-translational level, and induction of σ^B upon exposure to stress is through the phosphatase activity of RsbV on RsbW, which results in the dissociation of σ^B and RsbW [51]. Thus alterations in *sigB* transcript levels may not correlate with altered σ^B activity. However, in support of σ^B up-regulation, comparison of diclofenac-induced microarray data with publicly available microarray datasets using SAMMD [33] revealed that 46% of the genes which are regulated by σ^B are also altered in expression upon exposure to diclofenac. This included a 6-fold increase in *asp23*, encoding alkaline shock protein, and shown to be an indicator of σ^B -directed transcription [50,52,53].

Genes encoding virulence-associated proteins were significantly altered by diclofenac. For example, the staphylococcal respiratory response genes *srrA* and *srrB* were up-regulated 4.9- and 3.1-fold, respectively. When overexpressed, *srrAB* down-regulates virulence factors such as *agr* RNAIII, *tsst-1* and *spa*, and leads to a reduced virulence in a rabbit model of endocarditis [54-56]. The *srrAB* system is also up-regulated under conditions of anaerobic growth [57]. The sensory histidine kinase gene *saeS* was down-regulated -2.8-fold in the presence of diclofenac. Rogasch et al. [58] have shown that the loss of *saeS* and the response regulator *saeR*, results in reduced expression of extracellular and cell surface-associated virulence factors. In agreement with *saeS* down-regulation, *cap* genes encoding capsular polysaccharide serotype 5 (CP5) were shown to be up-regulated by diclofenac; an *saeS* mutant

demonstrates increased *cap* gene expression and CP5 production [59]. Down-regulated CP5 genes included those involved in chain-length determination (*cap5A* and *cap5B*) by -20.1- and -8.3-fold, as well as O-acetylation (*cap5H*) by -3.3-fold, respectively. Importantly, CP5 is one of the most prevalent *S. aureus* capsule serotypes among human clinical isolates [60], and strains null for CP5 production are more susceptible to phagocytosis, and are less virulent in a model of murine bacteremia [61-63].

Genes involved in central and energy metabolism, as well as in the metabolism of amino and fatty acids, DNA, and metabolic cofactors accounted for >30% of those significantly altered in response to diclofenac. This included the up-regulation of genes important for anaerobic growth, such as *srrAB* (above). In addition, the nitrate/nitrite respiration genes nitrate reductase (*narG*) and nitrite reductase (*nirB*) were strongly up-regulated 12.1- and 20.4-fold, and the nitrite transporter, *narK* was up-regulated 31-fold, respectively. Nitrate can be used by staphylococci as an alternative electron acceptor to drive oxidative phosphorylation, reducing nitrate to nitrite via nitrate reductase A (NarGHI) [64,65]. Nitrite can then be extruded from the cell via NarK, or it can be further reduced to ammonia by NirB. Nitrate reduction can also be coupled to the fermentation of organic acids such as formate to allow for survival in the presence of stressors which dissipate proton-motive force (PMF) [66,67]. Importantly, NSAIDs such as salicylate have been shown to uncouple oxidative phosphorylation and deplete PMF in mitochondria (reviewed in [68]). In support of organic acid fermentation in the presence of diclofenac, both formate (SACOL0301) and lactate (SACOL2363) transporters were strongly up-regulated 16.1- and 25.9-fold. Finally, genes of the urease operon (*ureABCEF* and *ureD*) were shown to be down-regulated (-3.5- to -11-fold) by diclofenac. These genes encode the urease enzyme (UreABC) or are accessory to its formation, and catalyze the conversion of urea to ammonia and carbon dioxide.

Diclofenac altered the expression of genes involved in DNA stability and repair. This included the down-regulation of *radA*, SACOL1154, *recU*, *topA*, *parC*, *xerD* and *nfo* (-2.0- to -3.7-fold). These encode a DNA repair protein, a DNA strand exchange inhibitor, an endonuclease, topoisomerase I and the A subunit of topoisomerase IV, a tyrosine recombinase, and endonuclease IV, respectively. Up-regulated DNA repair genes included *lexA* (2.6-fold), *hexA* (2-fold), SACOL0751 (2.6-fold), encoding the repressor of the global SOS DNA repair system, a mismatch-repair protein, and a putative photolyase, respectively. Genes of the pyrimidine DNA biosynthesis *pyr* operon were also strongly down-regulated (2.9- to 14.2-fold). This finding is concordant with a previous study demonstrating impaired DNA biosynthesis in response to growth of *E. coli* with diclofenac [19].

Quantitative real-time PCR (qRT-PCR) validation of microarray genes

Ten genes which were altered in expression as determined by microarray analysis were validated using qRT-PCR. This included genes with roles in antimicrobial resistance (*mepR*, *mepA*, SACOL2347), virulence (*cap5A*, *srrA*, *sigB*) metabolism (*nirB*, SACOL0301) and with other functions. The expression ratios of these genes were shown to be in strong agreement by correlation analysis ($r^2 = 0.92$) between both approaches (Additional File 2).

Diclofenac induced alterations in susceptibility to antibiotics

Diclofenac down-regulated structural and regulatory genes of drug transport systems and other mechanisms, which may lead to alterations in phenotypic resistance to antimicrobials. To examine this possibility, the susceptibility of lab and clinical strains to seven antibiotics was examined by determining agar diffusion minimum inhibitory concentrations (MICs) and by drug gradient plate analysis. MIC and gradient plate experiments revealed diclofenac to significantly increase susceptibility of *S. aureus* to three fluoroquinolone antibiotics in a concentration- and strain-dependent manner. For example, addition of 32 $\mu\text{g/ml}$ diclofenac reduced MICs for ciprofloxacin and norfloxacin in all strains (Table 2) ($P < 0.05$). MICs were reduced 2-fold in strains SH1000, COL, BB255 and SA1199A, and were reduced by 4- and 8-fold in WBG8287 and WGB9312, respectively. Increasing diclofenac to 64 $\mu\text{g/ml}$ further reduced ciprofloxacin MICs only for SH1000, but had no further impact on norfloxacin MICs. Interestingly, 32 $\mu\text{g/ml}$ diclofenac did not alter ofloxacin MICs for strains SH1000 and COL (MIC = 1 $\mu\text{g/ml}$) or for BB255 and WBG8287 (MIC = 0.5 $\mu\text{g/ml}$), but did decrease MICs for strains SA1199B and WGB9312 ($P < 0.05$) (Table 2). Increasing diclofenac to 64 $\mu\text{g/ml}$ further decreased ofloxacin MICs for SA1199B, but not for WGB9312. Gradient plate analysis for fluoroquinolones supported MIC data, where growth into plates containing 32 $\mu\text{g/ml}$ diclofenac was significantly reduced for SH1000 by 2.8-fold (ciprofloxacin) and 26-fold (norfloxacin) and for COL by 1.5-fold (ciprofloxacin) and 2.2-fold (norfloxacin), but not for ofloxacin for either strain ($P < 0.05$) (data not shown). Addition of 32 $\mu\text{g/ml}$ and 64 $\mu\text{g/ml}$ diclofenac did not significantly alter MICs for the protein synthesis inhibitors chloramphenicol or tetracycline.

Diclofenac was also observed to reduce susceptibility of *S. aureus* to the cell wall-active antibiotics oxacillin and vancomycin in a concentration- and strain-dependent manner. Addition of 32 $\mu\text{g/ml}$ diclofenac did not alter oxacillin MICs for SH1000 or BB255, but increased MICs for methicillin-resistant strains WBG8287, SA1199A and WGB9312 (Table 2). Increasing diclofenac to 64 $\mu\text{g/ml}$

Table 2 Effect of diclofenac on antibiotic susceptibility of COL, SH1000 and Dc^{RS} mutant derivatives

Antibiotic	Strain	MIC ^a (µg/ml)				
		Control	Dc ^b (32 µg/ml)	FI/FD ^c	Dc (64 µg/ml)	FI/FD
Ciprofloxacin	SH1000	0.5	0.25	-2	0.125	-4
	SC1-SC3 ^d	0.5	0.25	-2	0.125	-4
	COL	0.5	0.25	-2	0.25	-2
	SC4-SC6 ^d	0.5	0.5	0	0.25	-2
	BB255	0.25	0.125	-2	0.125	-2
	WGB8287	0.5	0.125	-4	0.125	-4
	SA1199B	8	4	-2	4	-2
	WBG9312	32	4	-8	4	-8
	All ^e	0.125	0.0625	-2	0.0625	-2
Norfloxacin	SA1199B	2	1	-2	0.5	-4
Ofloxacin	WBG9312	8	4	-2	4	-2
	SH1000	0.25	0.25	0	0.5	2
Oxacillin	SC1-3	0.25	0.5	2	0.5	2
	COL	>256	>256	ND	>256	ND
	SC4-6	>256	>256	ND	>256	ND
	BB255	0.25	0.25	0	0.25	0
	WGB8287	32	64	2	128	4
	SA1199B	0.13	0.25	2	0.5	4
	WBG9312	2	8	4	16	8

^a Minimum inhibitory concentration (MIC).

^b Diclofenac (Dc).

^c Fold increase (FI) or fold decrease (FD) in MIC and in the presence of Dcl.

^d Dc^{RS} mutant derivative isolates of SH1000 (SC1 through SC3) all had the same MICs; those of COL (SC4 through SC6) also all had the same MICs.

^e All (all strains in the study expressed the same MIC: SH1000, COL, SC1-SC6, BB255, WGB8287, SA1199B, and WBG9312).


increased oxacillin MICs for SH1000, and further increased MICs for WGB8287 and SA1199A, but not for WGB9312. Diclofenac did not alter MICs for vancomycin, but the addition of 32 µg/ml diclofenac did increase growth into vancomycin (2 µg/ml) gradient plates for strains SH1000 from 20 mm to 32 mm (1.6-fold) and WGB8287 from 21 mm to 31 mm (1.5-fold), but not COL and BB255. Gradient plate analysis is sensitive to small but important changes in resistance which may not be detectable by MIC assays. Collectively, the results reveal diclofenac to increase susceptibility to fluoroquinolone antibiotics, and to decrease susceptibility to antibiotics which target the cell wall. This effect of diclofenac on antibiotic susceptibility is strain-dependent, and is generally amplified as the concentration of diclofenac is increased.

The effect of selection for mutants expressing reduced susceptibility to diclofenac on resistance to antibiotics, and NSAIDs

To further understand the mechanism by which diclofenac alters resistance, mutants expressing reduced susceptibility to diclofenac (Dc^{RS}) were selected by plating overnight MHB cultures (>10⁹ CFU/ml) on 1X MIC (500 µg/ml) diclofenac gradients followed by incubation (24 h). Dc^{RS} mutants of both SH1000 and COL were

isolated from tightly-grouped colonies about 2/3 into the diclofenac gradient. For each strain, three Dc^{RS} mutants were selected and passaged several times on TSA in the absence of diclofenac. For Dc^{RS} mutants (SC1-SC6), diclofenac MICs in MHB increased 4-fold to 2000 µg/ml, and growth of Dc^{RS} mutant SC4 was more vigorous than COL in TSB containing 80 µg/ml diclofenac (Figure 1). Interestingly, SC4 also grew more vigorously in the absence of diclofenac relative to COL (Figure 1).

The Dc^{RS} mutants of COL and SH1000 did not demonstrate altered MICs for the antibiotics included in this study (Table 2). In addition, fluoroquinolone MICs in the presence of 32- and 64- µg/ml diclofenac did not differ between SH1000, COL and their respective Dc^{RS} mutants. Mutation to Dc^{RS} did however alter MICs in the presence of diclofenac for Oxa when compared to SH1000 and COL (Table 2). For example, Oxa MICs increased for Dc^{RS} mutants of SH1000 at 32 µg/ml diclofenac but not at 64 µg/ml, whereas the reverse was true for SH1000. In addition to conferring reduced susceptibility to diclofenac, mutation to Dc^{RS} significantly reduced susceptibility to the NSAID ibuprofen when compared to parent strains (P < 0.05), but did not alter susceptibility to the remaining NSAIDs, or to the salicylate analog, benzoate (Table 3).



Effect of diclofenac on ciprofloxacin accumulation

It has been shown previously that the reduced susceptibility of *S. aureus* to ciprofloxacin and ethidium bromide in the presence of salicylate correlates with reductions in the accumulation of these antimicrobials [10]. It was thus hypothesized that increased susceptibility of *S. aureus* grown with diclofenac may result from increased ciprofloxacin accumulation. To test this, accumulation of ciprofloxacin in strain BB255 grown with and without diclofenac was measured fluorometrically. Surprisingly, growth with 32 $\mu\text{g}/\text{ml}$ diclofenac resulted in a 29% reduction in ciprofloxacin from 188 ± 57 to 133 ± 19 ng/mg cells ($P = 0.01$, $N = 6$). Thus, salicylate

and diclofenac both reduce intracellular ciprofloxacin levels, but have opposite effects on resistance to ciprofloxacin: salicylate reduces susceptibility to ciprofloxacin [12], whereas diclofenac increases susceptibility.

Discussion

Diclofenac has been described as a non-antibiotic broad spectrum antibacterial, which can act in synergy with antibiotics to decrease bacterial cell counts. Support for the latter claim comes from studies showing reductions in MICs and in CFU/ml recovered from infected animals when diclofenac is administered in combination with the protein synthesis-inhibiting aminoglycosides streptomycin and gentamycin, and with the cell wall-active cephalosporins cefotiam and ceftriaxone [25,26,69-71]. For *S. aureus*, only reductions in streptomycin MICs have been reported [17]. How diclofenac is influencing the susceptibility of bacteria to antibiotics is unknown.

In the present study, growth with diclofenac significantly altered the susceptibility of lab and clinical *S. aureus* strains to five of seven antibiotics not previously tested. The study adds the fluoroquinolones ciprofloxacin, ofloxacin and norfloxacin to the list of antibiotics which significantly reduce MICs in the presence of diclofenac. Furthermore, this is the first study to demonstrate that growth with diclofenac can induce phenotypic resistance to antibiotics; namely, to the cell wall-active drugs oxacillin and vancomycin. As anticipated, microarray analysis of *S. aureus* strain COL grown with diclofenac revealed alterations in genes associated with regulation of antimicrobial resistance, and drug efflux. It is thus believed that diclofenac modifies intrinsic mechanisms of phenotypic antimicrobial resistance in *S. aureus*. Similar observations have been made for salicylate and other NSAIDs [7], suggesting that the mechanism by which these drugs influence resistance are at least partially allied. For salicylate, this includes alterations in efflux and a PMF-independent drug permeability barrier, as well as the involvement of MarR-family regulators such as SarA and MgrA [8-10]. In this study, diclofenac was not observed to significantly alter either *sarA* or *mgrA*, but did however strongly down-regulate drug efflux systems encoded by *mepRAB* and the *emrAB*-like operon SACOL2347-2348. Both MepRAB and EmrRAB are important for intrinsic resistance to fluoroquinolones, and *emrRAB* is inducible by salicylate [38,39,45]. It was thus suspected that reduced expression of these efflux systems, leading to intracellular accumulation of antibiotic, might explain the increased susceptibility to fluoroquinolones when grown with diclofenac (Table 2). Instead, diclofenac was observed to reduce intracellular ciprofloxacin levels similar to salicylate (29% for diclofenac, vs. 19% for salicylate) [10]. Importantly, salicylate-inducible resistance to ciprofloxacin can be

Table 3 Susceptibility of WT and diclofenac reduced susceptibility (Dc^{RS}) mutants to NSAIDs

Strain	Drug gradient plates (mg/ml) ^a					
	Ace (0→9)	Asa (0→3.6)	Ben (0→14.4)	Dc (0→0.5)	Ibu (0→4)	Sal (0→8)
SH1000	51 ± 4.2b	24 ± 1.0	54 ± 3.2	13 ± 1.5	0	24 ± 2.1
SC-1	51 ± 3.5	25 ± 0.6	52 ± 3.2	35 ± 5.4*	28 ± 2.3*	27 ± 0.6
COL	35 ± 1.2	22 ± 0.6	39 ± 3.2	23 ± 5.8	12 ± 1.5	31 ± 1.2
SC-4	35 ± 0.6	21 ± 1.5	31 ± 1.5	35 ± 3.6*	21 ± 0*	30 ± 1.2

^a Gradient plate technique; drug gradients prepared for acetaminophen (Ace), acetyl salicylic acid (Asa), benzoate (Ben), diclofenac (Dc), ibuprophen (Ibu), and sodium salicylate (Sal); concentration gradient provided in parentheses.

^b Average growth into NSAID gradients and standard deviation provided in mm.

* Denotes statistically significant difference between WT and Dc^{RS} by Student's t-test (P < 0.05).

conferred independent of active efflux [10]. Thus, changes in ciprofloxacin accumulation in the presence of diclofenac, and perhaps salicylate, may not be the direct cause of altered susceptibility to ciprofloxacin and other fluoroquinolones. It is important to note that strain BB255, used in ciprofloxacin accumulation assays, is a *rsbU* derivative, and thus is reduced in σ^B activation in response to stress [53,72]. This is perhaps significant, as an intact *sigB* (encoding σ^B) has been shown to be involved in intrinsic and salicylate-inducible resistance to antimicrobials [9,73], and the expression of *sigB* is up-regulated by salicylate [9], and by diclofenac (Additional File 2). Perhaps more importantly, RsbU has been reported to control the NorA drug efflux pump through MgrA [74]. It is therefore plausible that changes in strain BB255 which confer intrinsic resistance to fluoroquinolones differ mechanistically from those observed in *rsbU*⁺ strains. In support of this, ciprofloxacin MICs for BB255 were less than all other strains in the study, and reductions in ciprofloxacin MICs in the presence of diclofenac were more marked in *rsbU*⁺ SH1000 and in the other strains studied (Table 2).

Microarrays also revealed that growth in the presence of diclofenac down-regulates a substantial number of genes important for DNA stability and repair. Fluoroquinolone antibiotics interfere with DNA interactions between gyrase (GyrAB) or topo IV (ParCE), leading to breaks in DNA, and inducing global repair systems such as the SOS response [75,76]. An alternative explanation for the increased sensitivity of *S. aureus* grown with diclofenac to fluoroquinolones may therefore include a reduced ability for repair/turnover of damaged DNA leading to cell death. Interestingly, salicylate has also been shown to alter the expression of DNA biosynthesis/stability genes including *parE* in *S. aureus* [8], and the *pyr* genes in *Bacillus subtilis* [77], and to increase the frequency at which mutation to heritable antibiotic resistance occurs in *S. aureus* for both ciprofloxacin, and the steroid protein synthesis inhibitor fusidic acid [11,12]. Whether or not diclofenac can select for an increased frequency of genotypic resistance to antibiotics, and the significance of these expression differences in this, are important unanswered questions.

Diclofenac was observed to reduce susceptibility to the cell wall active antibiotics oxacillin and vancomycin. Oxacillin is a penicillinase-resistant β -lactam, and vancomycin is a glycopeptide antibiotic which targets D-alanyl-D-alanine residues in the cell wall, interfering with peptidoglycan biosynthesis. Genotypic resistance to these antibiotics is multifactorial, and includes both lateral gene acquisition and mutation(s) [78,79]. No mechanism of inducible phenotypic resistance to these antibiotics has been described. Moreover, salicylates have not been shown to induce phenotypic resistance to cell-wall active antibiotics. Growth in the presence of diclofenac led to the down-regulation of genes encoding the cell-wall associated penicillin-binding proteins PBP2 (*pbpB*) and PBP4 (*pbp4*), which are required for full resistance expression to β -lactams and vancomycin. For example, a mutation in the ORF of *pbp4* which abrogates PBP4 production has been identified in laboratory strains which express vancomycin resistance [46], and mutations in the regulatory region of *pbp4* which lead to PBP4 overproduction have been described in methicillin resistant strains [80]. Furthermore, Boyle-Vavra [81] demonstrated *pbpB* expression was up-regulated by both oxacillin and vancomycin. It is thus possible that *pbpB* and *pbp4* down-regulation induced by diclofenac contributes to reduced susceptibility to these drugs, the mechanism of which is presently unclear.

Mutation of *sigB* in COL, and in a vancomycin-intermediate *S. aureus* (VISA) strain, was shown to significantly reduce oxacillin and vancomycin MICs, respectively [82]. Moreover, *in vitro* selection of *S. aureus* mutants which express reduced susceptibility to household disinfectants has been shown to increase resistance to both oxacillin and vancomycin in a *sigB*-dependent manner [73,83]. Together, these findings suggest a role for σ^B in intrinsic resistance to antimicrobials which target components of the cell envelope. As diclofenac was determined to alter *sigB* expression by microarrays and qRT-PCR (Additional File 2), the increased expression may also be important for increased resistance to diclofenac-inducible oxacillin and vancomycin. Concordant with this, oxacillin MICs and growth into vancomycin gradients in the presence of diclofenac were not altered in *rsbU* strain BB255, but

increased for *rsbU*⁺ strain SH1000 (Table 2 and data not shown).

S. aureus mutants which express reduced susceptibility to diclofenac (Dc^{RS}) were not shown to differ in susceptibility to antibiotics compared to parent strains SH1000 or COL. Thus, the cellular alterations which occur at sub-MICs of diclofenac and alter antibiotic susceptibility (i.e. 32-64 µg/ml) are mechanistically-distinct from alterations associated with mutations leading to the Dc^{RS} phenotype selected from 1× MIC (500 µg/ml).

Diclofenac has been shown to significantly reduce *S. aureus* counts from rat granulomatous tissue in the absence of antibiotic [16]. This observation might result from host-specific effects (i.e. immune modulation), or bacterial-specific effects, such as inhibition of growth or altered virulence gene expression. In support of the latter, salicylic acid has been shown to repress *sarA* and SarA-inducible virulence genes such as *hla* (α-hemolysin) and *fnbA* (fibronectin-binding protein) in *S. aureus*, through upregulation of *sigB* [15,20,84]. Although diclofenac was also observed to up-regulate *sigB*, there was no attendant change in *sarA*, *hla* or *fnbA* expression levels. Similarly, up-regulation of *srrAB* did not lead to the down-regulation of SrrAB-repressed virulence genes such as *agr* RNA III, *tsst-1* or *spa*. Both *sigB* and *srrAB* products contribute to cellular functions other than pathogenesis including stress durability and anaerobic growth.

Conclusions

In summary, growth of *S. aureus* with subinhibitory concentrations of diclofenac was shown to alter the expression of hundreds of genes, including those associated with resistance to antimicrobials and with virulence. It was further shown that diclofenac increased the susceptibility of *S. aureus* to the fluoroquinolone antibiotics ciprofloxacin, norfloxacin and ofloxacin. These observations support previous studies which show diclofenac to increase susceptibility of *S. aureus* to the aminoglycoside streptomycin, and to reduce growth and survival of bacterial pathogens in animal models. Furthermore, this is the first study to show that diclofenac can also reduce susceptibility (induce phenotypic resistance) to antibiotics. Significant to *S. aureus*, this included the cell wall active drugs oxacillin and vancomycin, the latter of which is critical for the treatment of severe MRSA infections. The results of this study suggest that diclofenac modifies antimicrobial resistance in *S. aureus*, in part, by altering the expression of regulatory and structural genes associated with cell wall biosynthesis/turnover and transport.

Additional material

Additional file 1: Primers used for quantitative real-time PCR (qRT-PCR) in this study

Additional file 2: Genes up-regulated following diclofenac induction of *S. aureus* strain

Additional file 3: List of genes which encode hypothetical proteins and which were significantly altered in expression in response to diclofenac

Acknowledgements

All authors wish to acknowledge prior and ongoing support from the National Institutes of Health: SC1GM083882-01 (J.E.G.); R25 GM07667-30 (NMSU-MARC PROGRAM); S06-GM61222-05 (NMSU-MBRS-RISE PROGRAM); and P2ORR016480 from the NM-INBRE Program of the National Center for Research Resource.

Author details

¹Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL 33620, USA. ²Microbiology Group, Department of Biology and Molecular Biology Program, New Mexico State University, Las Cruces, NM 88003, USA. ³Department of Biology, Illinois State University, Normal, IL 61790, USA. ⁴Department of Biological Sciences, University of Southern Mississippi, Hattiesburg, MS 39406, USA. ⁵Bioinformatics and Computational Biosciences Branch (BCBB), OCICB/OSMO/OD/NIAID/NIH, Bethesda, MD 20892, USA.

Authors' contributions

JR, JG and BW conceived and supervised the study, and prepared the manuscript. JD, SCM, AKS, YS, SZ and NH performed experiments for microarrays, antibiotic susceptibility testing, qRT-PCR and ciprofloxacin accumulation assays. VN and ME contributed to the experimentation, design and data analysis of DNA microarrays. All authors have read and approved the final version.

Competing interests

The authors declare that they have no competing interests.

Received: 6 May 2011 Accepted: 21 July 2011 Published: 21 July 2011

References

1. Hiramatsu K, et al: Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J Antimicrob Chemother* 1997, **40**(1):135-6.
2. Lyon BR, Skurray R: Antimicrobial resistance of *Staphylococcus aureus*: genetic basis. *Microbiol Rev* 1987, **51**(1):88-134.
3. Neu HC: The crisis in antibiotic resistance. *Science* 1992, **257**(5073):1064-73.
4. Goldman JD, White DG, Levy SB: Multiple antibiotic resistance (*mar*) locus protects *Escherichia coli* from rapid cell killing by fluoroquinolones. *Antimicrob Agents Chemother* 1996, **40**(5):1266-9.
5. Rosner JL: Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in *Escherichia coli* K-12. *Proc Natl Acad Sci USA* 1985, **82**(24):8771-4.
6. Kumar A, HP Schweizer: Bacterial resistance to antibiotics: active efflux and reduced uptake. *Adv Drug Deliv Rev* 2005, **57**(10):1486-513.
7. Price CT, Lee IR, Gustafson JE: The effects of salicylate on bacteria. *Int J Biochem Cell Biol* 2000, **32**(10):1029-43.
8. Riordan JT, et al: Response of *Staphylococcus aureus* to salicylate challenge. *J Bacteriol* 2007, **189**(1):220-7.
9. Riordan JT, O'Leary JO, Gustafson JE: Contributions of *sigB* and *sarA* to distinct multiple antimicrobial resistance mechanisms of *Staphylococcus aureus*. *Int J Antimicrob Agents* 2006, **28**(1):54-61.
10. Price CT, Kaatz GW, Gustafson JE: The multidrug efflux pump NorA is not required for salicylate-induced reduction in drug accumulation by *Staphylococcus aureus*. *Int J Antimicrob Agents* 2002, **20**(3):206-13.
11. Price CT, Gustafson JE: Increases in the mutation frequency at which fusidic acid-resistant *Staphylococcus aureus* arise with salicylate. *J Med Microbiol* 2001, **50**(1):104-6.
12. Gustafson JE, et al: Growth in the presence of salicylate increases fluoroquinolone resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1999, **43**(4):990-2.

13. Eren A, et al: Chondroprotective effect of salicylate and chloroquine in pyogenic septic arthritis. *Adv Ther* 2008, **25**(2):133-42.
14. Sedlacek M, et al: Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. *Am J Kidney Dis* 2007, **49**(3):401-8.
15. Kupferwasser LI, et al: Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. *Circulation* 1999, **99**(21):2791-7.
16. Groppo FC, et al: Effect of sodium diclofenac on serum and tissue concentration of amoxicillin and on staphylococcal infection. *Biol Pharm Bull* 2004, **27**(1):52-5.
17. Dutta NK, et al: Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. *Int J Antimicrob Agents* 2007, **30**(3):242-9.
18. Annadurai S, et al: Antibacterial activity of the antiinflammatory agent diclofenac sodium. *Indian J Exp Biol* 1998, **36**(1):86-90.
19. Dastidar SG, et al: The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. *Int J Antimicrob Agents* 2000, **14**(3):249-51.
20. Kupferwasser LI, et al: Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. *J Clin Invest* 2003, **112**(2):222-33.
21. Muller E, et al: Mechanism of salicylate-mediated inhibition of biofilm in Staphylococcus epidermidis. *J Infect Dis* 1998, **177**(2):501-3.
22. Denkin S, et al: Gene expression profiling analysis of Mycobacterium tuberculosis genes in response to salicylate. *Arch Microbiol* 2005, **184**(3):152-7.
23. Pomposiello PJ, Bennik MH, Dimple B: Genome-wide transcriptional profiling of the Escherichia coli responses to superoxide stress and sodium salicylate. *J Bacteriol* 2001, **183**(13):3890-902.
24. Terada H: Uncouplers of oxidative phosphorylation. *Environ Health Perspect* 1990, **87**:213-8.
25. Annadurai S, et al: Experimental studies on synergism between aminoglycosides and the antimicrobial antiinflammatory agent diclofenac sodium. *J Chemother* 2002, **14**(1):47-53.
26. Joly V, et al: Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac. *J Pharmacol Exp Ther* 1988, **246**(2):695-700.
27. Cohen SP, McMurry LM, Levy SB: marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli. *J Bacteriol* 1988, **170**(12):5416-22.
28. Ravel G, et al: Cytokine release does not improve the sensitivity and specificity of the direct popliteal lymph node assay. *Toxicology* 2004, **200**(2-3):247-54.
29. Cohen SP, et al: Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. *J Bacteriol* 1993, **175**(24):7856-62.
30. Dastidar SG, et al: Evaluation of a synergistic combination between the non-antibiotic microbicides diclofenac and trifluoperazine. *Int J Antimicrob Agents* 2003, **21**(6):599-601.
31. Delgado A, et al: The fusidic acid stimulon of Staphylococcus aureus. *J Antimicrob Chemother* 2008, **62**(6):1207-14.
32. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci USA* 2001, **98**(9):5116-21.
33. Nagarajan V, Elsasri MO: SAMMD: Staphylococcus aureus microarray meta-database. *BMC Genomics* 2007, **8**:351.
34. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 2001, **29**(9):e45.
35. O'Leary JO, et al: Effects of sarA inactivation on the intrinsic multidrug resistance mechanism of Staphylococcus aureus. *FEMS Microbiol Lett* 2004, **237**(2):297-302.
36. Mortimer PG, Piddock LJ: A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. *J Antimicrob Chemother* 1991, **28**(5):639-53.
37. George AM, Levy SB: Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline. *J Bacteriol* 1983, **155**(2):531-40.
38. Kaatz GW, McAleese F, Seo SM: Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. *Antimicrob Agents Chemother* 2005, **49**(5):1857-64.
39. Kaatz GW, DeMarco CE, Seo SM: MepR, a repressor of the Staphylococcus aureus MATE family multidrug efflux pump MepA, is a substrate-responsive regulatory protein. *Antimicrob Agents Chemother* 2006, **50**(4):1276-81.
40. McAleese F, et al: A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. *Antimicrob Agents Chemother* 2005, **49**(5):1865-71.
41. Ramos JL, et al: The TetR family of transcriptional repressors. *Microbiol Mol Biol Rev* 2005, **69**(2):326-56.
42. Schumacher MA, et al: Structural mechanisms of QacR induction and multidrug recognition. *Science* 2001, **294**(5549):2158-63.
43. Brown MH, Skurray RA: Staphylococcal multidrug efflux protein QacA. *J Mol Microbiol Biotechnol* 2001, **3**(2):163-70.
44. Lomovskaya O, Lewis K: Emr, an Escherichia coli locus for multidrug resistance. *Proc Natl Acad Sci USA* 1992, **89**(19):8938-42.
45. Lomovskaya O, Lewis K, Matin A: EmrR is a negative regulator of the Escherichia coli multidrug resistance pump EmrAB. *J Bacteriol* 1995, **177**(9):2328-34.
46. Sieradzki K, Pinho MG, Tomasz A: Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. *J Biol Chem* 1999, **274**(27):18942-6.
47. Peschel A, et al: Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. *J Biol Chem* 1999, **274**(13):8405-10.
48. Wu S, de Lencastre H, Tomasz A: Sigma-B, a putative operon encoding alternate sigma factor of Staphylococcus aureus RNA polymerase: molecular cloning and DNA sequencing. *J Bacteriol* 1996, **178**(20):6036-42.
49. Pane-Farre J, et al: The sigmaB regulon in Staphylococcus aureus and its regulation. *Int J Med Microbiol* 2006, **296**(4-5):237-58.
50. Miyazaki E, et al: The Staphylococcus aureus rsbW (orf159) gene encodes an anti-sigma factor of SigB. *J Bacteriol* 1999, **181**(9):2846-51.
51. Senn MM, et al: Molecular analysis and organization of the sigmaB operon in Staphylococcus aureus. *J Bacteriol* 2005, **187**(23):8006-19.
52. Kullik II, Giachino P: The alternative sigma factor sigmaB in Staphylococcus aureus: regulation of the sigB operon in response to growth phase and heat shock. *Arch Microbiol* 1997, **167**(2/3):151-9.
53. Giachino P, Engelmann S, Bischoff M: Sigma(B) activity depends on RsbU in Staphylococcus aureus. *J Bacteriol* 2001, **183**(6):1843-52.
54. Pragman AA, et al: Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus. *J Bacteriol* 2004, **186**(8):2430-8.
55. Throup JP, et al: The srhSR gene pair from Staphylococcus aureus: genomic and proteomic approaches to the identification and characterization of gene function. *Biochemistry* 2001, **40**(34):10392-401.
56. Yarwood JM, McCormick JK, Schlievert PM: Identification of a novel two-component regulatory system that acts in global regulation of virulence factors of Staphylococcus aureus. *J Bacteriol* 2001, **183**(4):1113-23.
57. Fuchs S, et al: Anaerobic gene expression in Staphylococcus aureus. *J Bacteriol* 2007, **189**(11):4275-89.
58. Rogasch K, et al: Influence of the two-component system SaeRS on global gene expression in two different Staphylococcus aureus strains. *J Bacteriol* 2006, **188**(22):7742-58.
59. Steinhuber A, et al: Molecular architecture of the regulatory Locus sae of Staphylococcus aureus and its impact on expression of virulence factors. *J Bacteriol* 2003, **185**(21):6278-86.
60. O'Riordan K, Lee JC: Staphylococcus aureus capsular polysaccharides. *Clin Microbiol Rev* 2004, **17**(1):218-34.
61. Bhasin N, et al: Identification of a gene essential for O-acetylation of the Staphylococcus aureus type 5 capsular polysaccharide. *Mol Microbiol* 1998, **27**(1):9-21.
62. Thakker M, et al: Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. *Infect Immun* 1998, **66**(11):5183-9.
63. Karakawa WW, et al: Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. *Infect Immun* 1988, **56**(5):1090-5.

64. Burke KA, Lascelles J: Nitrate reductase system in *Staphylococcus aureus* wild type and mutants. *J Bacteriol* 1975, **123**(1):308-16.
65. Hoffmann T, et al: The anaerobic life of *Bacillus subtilis*: cloning of the genes encoding the respiratory nitrate reductase system. *FEMS Microbiol Lett* 1995, **131**(2):219-25.
66. Stewart V: Nitrate respiration in relation to facultative metabolism in enterobacteria. *Microbiol Rev* 1988, **52**(2):190-232.
67. Bonnefoy V, et al: Autoregulation of the nar operon encoding nitrate reductase in *Escherichia coli*. *Mol Gen Genet* 1986, **204**(1):180-4.
68. Lewis K, et al: Bacterial resistance to uncouplers. *J Bioenerg Biomembr* 1994, **26**(6):639-46.
69. Dutta NK, Mazumdar K, Park JH: In vitro synergistic effect of gentamicin with the anti-inflammatory agent diclofenac against *Listeria monocytogenes*. *Letts Appl Microbiol* 2009, **48**(6):783-5.
70. Mazumdar K, et al: The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. *Eur J Clin Microbiol Infect Dis* 2009, **28**(8):881-91.
71. Dutta NK, et al: Activity of diclofenac used alone and in combination with streptomycin against *Mycobacterium tuberculosis* in mice. *Int J Antimicrob Agents* 2007, **30**(4):336-40.
72. Voelker U, et al: Separate mechanisms activate sigma B of *Bacillus subtilis* in response to environmental and metabolic stresses. *J Bacteriol* 1995, **177**(13):3771-80.
73. Price CT, et al: Pine oil cleaner-resistant *Staphylococcus aureus*: reduced susceptibility to vancomycin and oxacillin and involvement of SigB. *Appl Environ Microbiol* 2002, **68**(11):5417-21.
74. Truong-Bolduc QC, Hooper DC: Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of *Staphylococcus aureus*. *J Bacteriol* 192(10):2525-34.
75. Salles B, Defais M: Signal of induction of recA protein in *E. coli*. *Mutat Res* 1984, **131**(2):53-9.
76. Piddock LJ, Walters RN, Diver JM: Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in *Escherichia coli*. *Antimicrob Agents Chemother* 1990, **34**(12):2331-6.
77. Duy NV, et al: The proteome and transcriptome analysis of *Bacillus subtilis* in response to salicylic acid. *Proteomics* 2007, **7**(5):698-710.
78. Katayama Y, Ito T, Hiramatsu K: A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2000, **44**(6):1549-55.
79. Hiramatsu K: Vancomycin-resistant *Staphylococcus aureus*: a new model of antibiotic resistance. *Lancet Infect Dis* 2001, **1**(3):147-55.
80. Henze UU, Berger-Bachi B: *Staphylococcus aureus* penicillin-binding protein 4 and intrinsic beta-lactam resistance. *Antimicrob Agents Chemother* 1995, **39**(11):2415-22.
81. Boyle-Vavra S, et al: Transcriptional induction of the penicillin-binding protein 2 gene in *Staphylococcus aureus* by cell wall-active antibiotics oxacillin and vancomycin. *Antimicrob Agents Chemother* 2003, **47**(3):1028-36.
82. Singh VK, et al: Impact of sigB mutation on *Staphylococcus aureus* oxacillin and vancomycin resistance varies with parental background and method of assessment. *Int J Antimicrob Agents* 2003, **21**(3):256-61.
83. Davis AO, et al: Characterization of *Staphylococcus aureus* mutants expressing reduced susceptibility to common house-cleaners. *J Appl Microbiol* 2005, **98**(2):364-72.
84. Palma M, et al: Salicylic acid activates sigma factor B by rsbU-dependent and -independent mechanisms. *J Bacteriol* 2006, **188**(16):5896-903.
85. Horsburgh MJ, et al: sigmaB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from *Staphylococcus aureus* 8325-4. *J Bacteriol* 2002, **184**(19):5457-67.
86. Kornblum J, et al: Conversion of a homogeneously methicillin-resistant strain of *Staphylococcus aureus* to heterogeneous resistance by Tn551-mediated insertional inactivation. *Eur J Clin Microbiol* 1986, **5**(6):714-8.
87. Berger-Bachi B, et al: Mapping and characterization of multiple chromosomal factors involved in methicillin resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1992, **36**(7):1367-73.

doi:10.1186/1476-0711-10-30

Cite this article as: Riordan et al: Alterations in the transcriptome and antibiotic susceptibility of *Staphylococcus aureus* grown in the presence of diclofenac. *Annals of Clinical Microbiology and Antimicrobials* 2011 **10**:30.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

